SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2023 and to highlight recent corporate progress.
Conference Call & Webcast Details
| Date: | Tuesday, May 9th, 2023 |
| Time: | 4:30 p.m. ET |
| Live call: | Toll-Free: (800) 715-9871 Conference ID: 4068548 |
| Webcast: | https://edge.media-server.com/mmc/p/tw7qar43 |
Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano’s investor relations website at https://ir.bionano.com/ for at least 30 days.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.10 |
| Daily Change: | 0.05 1.19 |
| Daily Volume: | 41,129 |
| Market Cap: | US$572.980M |
April 08, 2025 March 31, 2025 March 18, 2025 March 13, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
